Equities analysts expect that CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will post earnings per share (EPS) of ($0.04) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for CASI Pharmaceuticals’ earnings. CASI Pharmaceuticals posted earnings per share of ($0.03) in the same quarter last year, which suggests a negative year over year growth rate of 33.3%. The company is scheduled to issue its next earnings results on Monday, November 13th.

On average, analysts expect that CASI Pharmaceuticals will report full year earnings of ($0.15) per share for the current year, with EPS estimates ranging from ($0.15) to ($0.14). For the next year, analysts expect that the firm will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.16) to ($0.15). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow CASI Pharmaceuticals.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.01).

Several research analysts have commented on the stock. ValuEngine upgraded shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. Finally, Maxim Group restated a “buy” rating and issued a $4.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th.

ILLEGAL ACTIVITY WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/01/0-04-eps-expected-for-casi-pharmaceuticals-inc-casi-this-quarter.html.

In related news, Director Wei-Wu He purchased 207,502 shares of CASI Pharmaceuticals stock in a transaction dated Tuesday, September 19th. The stock was bought at an average cost of $1.75 per share, with a total value of $363,128.50. Following the purchase, the director now owns 513,525 shares in the company, valued at approximately $898,668.75. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders bought 996,329 shares of company stock valued at $1,647,138. Company insiders own 13.01% of the company’s stock.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Get a free copy of the Zacks research report on CASI Pharmaceuticals (CASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.